Nexien Biopharma Inc
OTC:NXEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nexien Biopharma Inc
Free Cash Flow
Nexien Biopharma Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nexien Biopharma Inc
OTC:NXEN
|
Free Cash Flow
-$61.8k
|
CAGR 3-Years
4%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Free Cash Flow
$19.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Free Cash Flow
$12.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
26%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Free Cash Flow
$9.1B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Free Cash Flow
$12.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Free Cash Flow
$6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
Nexien Biopharma Inc
Glance View
Nexien BioPharma, Inc. engages in the development and commercialization of Food and Drug Administration-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company is headquartered in Glendale, Colorado. The company went IPO on 2001-07-11. The firm is engaged in the development of drugs containing cannabinoids for the treatment of various diseases, disorders and medical conditions, and owns a license covering certain intellectual property, including certain patent applications. The Company’s subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
See Also
What is Nexien Biopharma Inc's Free Cash Flow?
Free Cash Flow
-69.7k
USD
Based on the financial report for Dec 31, 2024, Nexien Biopharma Inc's Free Cash Flow amounts to -69.7k USD.
What is Nexien Biopharma Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
28%
Over the last year, the Free Cash Flow growth was -12%. The average annual Free Cash Flow growth rates for Nexien Biopharma Inc have been 4% over the past three years , 28% over the past five years .
